![Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges | Journal of the American Heart Association Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/b8939236-6c55-4646-946f-998500325506/jah35265-fig-0001.png)
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges | Journal of the American Heart Association
![Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know - Conway - 2017 - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Wiley Online Library Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know - Conway - 2017 - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Wiley Online Library](https://accpjournals.onlinelibrary.wiley.com/cms/asset/3467d178-a6da-4a79-888e-1ee3a8b6d20e/phar.2017.37.issue-2.cover.jpg?trick=1677448186758)
Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know - Conway - 2017 - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Wiley Online Library
![The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review | International Journal of Emergency Medicine | Full Text The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review | International Journal of Emergency Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12245-018-0215-6/MediaObjects/12245_2018_215_Fig1_HTML.png)
The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review | International Journal of Emergency Medicine | Full Text
![Reasons for Nonadherence to the Direct Oral Anticoagulant Apixaban: A Cross-Sectional Survey of Atrial Fibrillation Patients | JACC: Advances Reasons for Nonadherence to the Direct Oral Anticoagulant Apixaban: A Cross-Sectional Survey of Atrial Fibrillation Patients | JACC: Advances](https://www.jacc.org/cms/asset/4fcdd5be-0bc0-4e9c-8a20-a6ff86064e47/fx1.jpg)
Reasons for Nonadherence to the Direct Oral Anticoagulant Apixaban: A Cross-Sectional Survey of Atrial Fibrillation Patients | JACC: Advances
![Apixaban anti-Xa activity (ng/mL) and clinical characteristics for the... | Download Scientific Diagram Apixaban anti-Xa activity (ng/mL) and clinical characteristics for the... | Download Scientific Diagram](https://www.researchgate.net/publication/321762744/figure/tbl1/AS:775712122363904@1561955590351/Apixaban-anti-Xa-activity-ng-mL-and-clinical-characteristics-for-the-entire-group-and.png)
Apixaban anti-Xa activity (ng/mL) and clinical characteristics for the... | Download Scientific Diagram
![Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges | Journal of the American Heart Association Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/9d03411e-2e57-44d7-81b6-4a6c6578e733/jah35265-fig-0003.png)
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges | Journal of the American Heart Association
![Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group](https://i0.wp.com/pharmaceuticalintelligence.com/wp-content/uploads/2020/07/wc-3.png?resize=500%2C308&ssl=1)
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
![UPDATE ON THE DIRECT ORAL ANTICOAGULANTS (DOACs): WHERE ARE WE IN THE LABORATORY ALMOST TEN YEARS LATER? - DiaPharma UPDATE ON THE DIRECT ORAL ANTICOAGULANTS (DOACs): WHERE ARE WE IN THE LABORATORY ALMOST TEN YEARS LATER? - DiaPharma](https://diapharma.com/wp-content/uploads/2019/02/clot-club-doacs-8.jpg)
UPDATE ON THE DIRECT ORAL ANTICOAGULANTS (DOACs): WHERE ARE WE IN THE LABORATORY ALMOST TEN YEARS LATER? - DiaPharma
![Eliquis.pdf - ACTIVE LEARNING TEMPLATE: Medication Zulayka Sanchez STUDENT NAME Eliquis MEDICATION REVIEW MODULE CHAPTER CATEGORY CLASS | Course Hero Eliquis.pdf - ACTIVE LEARNING TEMPLATE: Medication Zulayka Sanchez STUDENT NAME Eliquis MEDICATION REVIEW MODULE CHAPTER CATEGORY CLASS | Course Hero](https://www.coursehero.com/thumb/99/29/99290cabad7ebc90c129a32897198b6b0c15aa77_180.jpg)
Eliquis.pdf - ACTIVE LEARNING TEMPLATE: Medication Zulayka Sanchez STUDENT NAME Eliquis MEDICATION REVIEW MODULE CHAPTER CATEGORY CLASS | Course Hero
![Frontiers | Protocol for AREST: Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation—A Randomized Controlled Trial of Early Anticoagulation After Acute Ischemic Stroke in Atrial Fibrillation Frontiers | Protocol for AREST: Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation—A Randomized Controlled Trial of Early Anticoagulation After Acute Ischemic Stroke in Atrial Fibrillation](https://www.frontiersin.org/files/Articles/478395/fneur-10-00975-HTML/image_m/fneur-10-00975-g001.jpg)